Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- MHLW Lifts Request for Kaketsuken to Suspend Flu Vaccine Shipment
October 23, 2015
- Chuikyo OKs Expansion of Health Coverage for Investigator-Led Trials
October 22, 2015
- Impact of Z2 Rule to Be Discussed toward FY2016 Reform: MHLW
October 22, 2015
- New MHLW Economic Affairs Chief Visits Logistics Center, Says Distribution Key to Brightening Pharma Sector
October 22, 2015
- MHLW Likely to Announce 5 or So Sakigake Products Next Week
October 22, 2015
- Add Interstitial Pneumonia to Daklinza, Sunvepra Labels: MHLW
October 21, 2015
- MHLW to Show Detailed Steps to Foster Pharma Sector in November
October 21, 2015
- Patent Extension, Patent Linkage Rules in TPP Require No Rule Changes in Japan: MHLW Official
October 20, 2015
- 5 Members to Leave Chuikyo before Full-Fledged Debate Begins for 2016 Reform
October 20, 2015
- Govt to Reduce Stockpiles of Anti-Pandemic Flu Drugs
October 19, 2015
- PAFSC 1st Committee to Discuss Lexapro for Social Anxiety Disorder on Oct. 30
October 19, 2015
- AMED to Launch Project to Fund Orphan Drug Hopefuls
October 19, 2015
- AMED’s Joint Drug Discovery Project to See Match-Ups by the End of October: President Suematsu
October 16, 2015
- Chuikyo Subcommittee OKs 70% Threshold for DPC Incentive
October 16, 2015
- Additional Indication of Xeloda, Elplat to Be Reported to PAFSC’s 2nd Committee on Oct. 29
October 16, 2015
- High Unmet Medical Need for Lenalidomide: Council on Unapproved Drugs
October 16, 2015
- MHLW Council on Unapproved Drugs to Review Appropriateness of Humanitarian Trials, Notification Due Out November
October 15, 2015
- Chuikyo Subcommittee Roughly OKs Sakigake Pricing Premium, Yet No Agreement on Rate Raise
October 15, 2015
- Chuikyo Payer Reps Wary of Revising Foreign Price Adjustment Rule for Govt-Requested Drugs
October 15, 2015
- Chuikyo Tilting Toward Introduction of Re-Pricing for “Huge Seller” Drugs
October 15, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…